Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients
NCT ID: NCT04802018
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2021-03-09
2022-12-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For the development of the study, 500 individuals with COVID-19 in home confinement will be randomly assigned to form part of the control group, which will be followed conventionally by Primary Care Professionals, or to the experimental group, which will also be provided with the wearable device for non-invasive multimodal monitoring linked to an App for transfering data. Furthermore, the patient will be able to interact with the application on three times daily by indicating the symptoms contemplated and answering the decision clinical questions. In this way, alarms can be generated in the presence of symptoms or significant alterations in the parameters monitored by the device, which the health professionals of the Primary Care teams included in the study will evaluate at the appropriate time, taking the best decision in each case.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Secure Self-monitoring Through a Combination of Connected Objects: Implementation in COVID-19 Patients Monitored at Home
NCT04560855
Development and Validation of a Telemonitoring System for High-risk Cardiovascular Patients
NCT05485532
Remote Symptom Review in Patients With Implantable Diagnostic Holter
NCT06431828
COVID-19 Surveillance Based on Smart Wearable Device
NCT04459637
COVID-19 Watch + COVID-19 Pulse
NCT04581863
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Baseline variables:
* Age, sex, date of COVID-19 positive diagnosis (PCR or antigen test).
* Stage of clinical progression of the disease: according to the Primary Care COVID-19 management
* Information collected in the telephone clinical assessment questionnaire in the home follow-up of the patient with SARS-CoV-2 infection
Variables generated by the study follow-up:
* Vital signs covered by the Bakeey E66 smartwatch device: temperature, respiration rate (RR), heart rate (HR) and oxygen saturation (SatO2)
* Clinical symptoms covered by the Home App for submission by the patient: cough, fever, chest pain, respiratory distress (dyspnoea), vomiting and diarrhoea.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Monitored group
Monitoring of vital signs and following with the conventional telephone protocol
Clinical decision support system based on non-invasive multimodal monitoring
Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
Control group
Conventional telephone follow-up by health staff
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clinical decision support system based on non-invasive multimodal monitoring
Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acceptance to sign the informed consent document.
* Possession of a Smartphone or Tablet with Internet connection.
* Possession of mental faculties to participate in the study.
Exclusion Criteria
* Lack of digital skills to use the Home App.
* Cognitive impairment that prevents the patient from participating in the study.
* Disabling pathology of the upper limb.
16 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Clínico Universitario de Valladolid
OTHER
University of Valladolid
OTHER
Sanidad de Castilla y León
OTHER
Increase-Tech
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Juan Francisco Arenillas Lara
Phd, physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan Francisco Arenillas Lara, PhD
Role: PRINCIPAL_INVESTIGATOR
Study Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine of Valladolid
Valladolid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CASVE-NM-21-508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.